It acts as a CB1 receptor agonist with a pKB value of 7.2 and demonstrates that replacing the ketone in 3-carbonylindoles with an oxadiazole spacer does not generally lead to activity loss.[2][3]
^Shevyrin V, Melkozerov V, Eltsov O, Shafran Y, Morzherin Y (February 2016). "Synthetic cannabinoid 3-benzyl-5-[1-(2-pyrrolidin-1-ylethyl)-1H-indol-3-yl]-1,2,4-oxadiazole. The first detection in illicit market of new psychoactive substances". Forensic Science International. 259: 95–100. doi:10.1016/j.forsciint.2015.12.019. PMID26771874.
^Moloney GP, Angus JA, Robertson AD, Stoermer MJ, Robinson M, Wright CE, et al. (March 2008). "Synthesis and cannabinoid activity of 1-substituted-indole-3-oxadiazole derivatives: novel agonists for the CB1 receptor". European Journal of Medicinal Chemistry. 43 (3): 513–39. doi:10.1016/j.ejmech.2007.04.007. PMID17582659.